HLS Therapeutics (TSE:HLS) Releases Earnings Results

HLS Therapeutics (TSE:HLS) issued its quarterly earnings data on Thursday. The company reported C($0.10) EPS for the quarter, FiscalAI reports. HLS Therapeutics had a negative return on equity of 14.39% and a negative net margin of 15.26%. The firm had revenue of C$20.15 million during the quarter.

Here are the key takeaways from HLS Therapeutics’ conference call:

• Cardiovascular growth lifted Q3 results: Revenue rose 5% year over year to $14.2 million, while Adjusted EBITDA was $5.0 million versus $4.9 million a year earlier. The cardiovascular portfolio grew approximately 21% in local currency and generated $0.7 million in direct brand contribution.
• NILEMDO’s launch is gaining traction: Sales increased 91% sequentially to more than CAD 800,000, with 2,900 patient starts since launch and private coverage now reaching over 80% of privately insured Canadians. HLS expects public-payer negotiations to begin this quarter and, pending approval, plans to launch NEXLIZET in the first half of 2027.
• 2026 Adjusted EBITDA is expected in the lower half of guidance ($18.5 million–$21 million), although revenue is expected near the midpoint of its $56 million–$60 million range. HLS cited additional NILEMDO investment and a faster shift toward cardiovascular products, which currently have lower margins than Clozaril.
• Clozaril results remain mixed: Canadian Q3 sales declined 2.6% in local currency, while U.S. sales were flat year over year and down 6.5% year to date. Management said patient volumes have grown sequentially in recent months, but remain below their 2025 peak.
• HLS added VERQUVO to its cardiovascular portfolio through a capital-efficient Canadian commercialization agreement with Bayer; the company expects modest near-term contribution and estimates peak sales potential of $5 million–$10 million. Management expects growth to step up in 2027 and accelerate in 2028, supported by NILEMDO, potential NEXLIZET approval, and VERQUVO.

HLS Therapeutics Stock Down 11.7%

Shares of HLS stock opened at C$3.70 on Friday. The company has a current ratio of 1.05, a quick ratio of 1.01 and a debt-to-equity ratio of 75.86. HLS Therapeutics has a 12 month low of C$3.56 and a 12 month high of C$5.25. The stock has a market cap of C$114.46 million, a P/E ratio of -13.70 and a beta of -0.52. The company has a 50 day simple moving average of C$4.11 and a two-hundred day simple moving average of C$4.29.

Analyst Ratings Changes

A number of research analysts have weighed in on HLS shares. Raymond James Financial raised HLS Therapeutics from an “outperform” rating to a “strong-buy” rating and increased their target price for the company from C$7.00 to C$8.00 in a report on Friday, August 14th. Canaccord Genuity Group raised HLS Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, August 13th. One analyst has rated the stock with a Strong Buy rating and one has given a Buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Strong Buy” and an average price target of C$8.00.

About HLS Therapeutics

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue.